Avid Bioservices Inc (CDMO)

[biopharm]

Trademark "BETABODY" just updated last week

________

DATA PRESENTED AT AACR ANNUAL MEETING SUPPORT TARGETED IMMUNE REACTIVATION MECHANISM AND POTENTIAL OF PEREGRINE'S BAVITUXIMAB IN SOLID TUMOR THERAPY

April 10, 2013
...

Researchers also presented details of new PS-binding constructs(4). Termed "betabodies," the molecules consist of the PS-binding domain of the serum protein ß2-glycoprotein I (ß2GPI), fused to the constant region of an antibody. Betabodies bind to PS directly, are smaller in size and have a longer serum half-life than natural antibodies. Early studies indicate that betabodies hold potential as next-generation PS-binding agents that have the potential to be used for a broad number of applications including antibody-drug conjugates and next generation therapeutics for oncology and infectious diseases.
...


http://ir.avidbio.com/news-releases/news-release-details/data-presented-aacr-annual-meeting-support-targeted-immune

_________

Feb 12, 2018

TUSTIN, Calif. and BOSTON, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (“Avid”) and Oncologie, Inc. today announced that the companies have entered into an Asset Assignment and Purchase Agreement for Avid’s phosphatidylserine (PS)-targeting program including bavituximab. Bavituximab is an investigational immune-modulatory monoclonal antibody that targets PS, a phospholipid that inhibits the ability of immune cells to recognize and fight tumors. In addition to bavituximab, the deal includes Avid’s other PS-targeting antibodies, including betabodies, as well as certain other assets and licenses useful and/or necessary for the potential commercialization of bavituximab.

Under terms of the agreement, Avid will receive an aggregate of $8 million in upfront payments from Oncologie paid over a period of six months from the execution date of the agreement and will be eligible to receive up to $95 million in development, regulatory and commercialization milestones. Oncologie will be responsible for all future research, development and commercialization of bavituximab, and related intellectual property costs, with Avid receiving royalties on net sales that are upward tiering into the mid-teens. As part of the deal, Oncologie will also enter into an agreement with Avid for future contract development and manufacturing activities in support of bavituximab. Roth Capital Partners acted as financial advisor to Avid in this transaction, rendering a Fairness Opinion to its board of directors.

...

https://www.pm360online.com/avid-bioservices-and-oncologie-enter-into-asset-assignment-and-purchase-agreement-for-avids-ps-targeting-program-including-bavituximab/amp/

____________

Trademark for "BETABODY" updated just this month ...Oct 14, 2019

Oct 14 2019

COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED

https://trademarks.justia.com/862/48/betabody-86248425.html